PTGX (STOCKS)
Protagonist Therapeutics, Inc
$104.720000
+7.150000 (+7.33%)
Prev close: $97.570000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Dinesh V. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,680.13M
- Employees
- 130
- P/E (TTM)
- -47.77
- P/B (TTM)
- 9.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.69 | $-0.50 | -0.1917 | -38.47% |
|
Sep 2025 (Q3)
|
$-0.62 | $-0.65 | +0.0318 | +4.88% |
|
Jun 2025 (Q2)
|
$-0.55 | $-0.59 | +0.0400 | +6.78% |
|
Mar 2025 (Q1)
|
$-0.19 | $-0.24 | +0.0457 | +19.39% |
Financial Statements
| Revenues | $46.02M |
| Benefits Costs and Expenses | $175.33M |
| Costs And Expenses | $175.33M |
| Operating Expenses | $204.14M |
| Research and Development | $159.29M |
| Other Operating Expenses | $44.85M |
| Operating Income/Loss | -$158.13M |
| Income/Loss From Continuing Operations After Tax | -$130.15M |
| Income/Loss From Continuing Operations Before Tax | -$129.31M |
| Income Tax Expense/Benefit | $838.00K |
| Income Tax Expense/Benefit, Current | $838.00K |
| Net Income/Loss | -$130.15M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$130.15M |
| Net Income/Loss Available To Common Stockholders, Basic | -$130.15M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.05 |
| Diluted Earnings Per Share | -$2.05 |
| Basic Average Shares | 63,573,048 |
| Diluted Average Shares | 63,573,048 |
| Assets | $668.19M |
| Current Assets | $577.57M |
| Noncurrent Assets | $90.61M |
| Fixed Assets | $3.86M |
| Other Non-current Assets | $86.75M |
| Liabilities | $53.48M |
| Current Liabilities | $45.44M |
| Accounts Payable | $5.34M |
| Other Current Liabilities | $40.10M |
| Noncurrent Liabilities | $8.04M |
| Equity | $614.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $614.71M |
| Liabilities And Equity | $668.19M |
| Net Cash Flow From Operating Activities | $57.67M |
| Net Cash Flow From Operating Activities, Continuing | $57.67M |
| Net Cash Flow From Investing Activities | -$49.33M |
| Net Cash Flow From Investing Activities, Continuing | -$49.33M |
| Net Cash Flow From Financing Activities | $22.86M |
| Net Cash Flow From Financing Activities, Continuing | $22.86M |
| Net Cash Flow | $31.20M |
| Net Cash Flow, Continuing | $31.20M |
| Comprehensive Income/Loss | -$129.43M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$129.43M |
| Other Comprehensive Income/Loss | $723.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $723.00K |